Understanding the costs of drug-related actions is an important aspect of drug policy. Some of the funds allocated by governments for expenditure on tasks related to drugs are identified as such in the budget (‘labelled’). Often, however, most drug-related expenditure is not identified (‘unlabelled’) and must be estimated using modelling approaches.
In Germany, drug policy and most treatment systems follow an integrated approach to licit and illicit substances, making it difficult to identify expenditure related to illicit drugs only. Since the funding of most drug initiatives is the responsibility of the Länder, the federal government and local governments, as well as the social security services, information on drug-related expenditure is not aggregated regularly.